These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9987151)

  • 1. Association of human leucocyte antigen phenotype with vaccine efficacy in patients receiving vaginal mucosal immunization for recurrent urinary tract infection.
    Hopkins WJ; Heisey DM; Uehling DT
    Vaccine; 1999 Jan; 17(2):169-71. PubMed ID: 9987151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaginal mucosal immunization for recurrent urinary tract infection: extended phase II clinical trial.
    Uehling DT; Hopkins WJ; Beierle LM; Kryger JV; Heisey DM
    J Infect Dis; 2001 Mar; 183 Suppl 1():S81-3. PubMed ID: 11171022
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial.
    Hopkins WJ; Elkahwaji J; Beierle LM; Leverson GE; Uehling DT
    J Urol; 2007 Apr; 177(4):1349-53; quiz 1591. PubMed ID: 17382730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 clinical trial of a vaginal mucosal vaccine for urinary tract infections.
    Uehling DT; Hopkins WJ; Elkahwaji JE; Schmidt DM; Leverson GE
    J Urol; 2003 Sep; 170(3):867-9. PubMed ID: 12913718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal mucosal immunization for recurrent urinary tract infection: phase II clinical trial.
    Uehling DT; Hopkins WJ; Balish E; Xing Y; Heisey DM
    J Urol; 1997 Jun; 157(6):2049-52. PubMed ID: 9146577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection.
    Uehling DT; Hopkins WJ; Dahmer LA; Balish E
    J Urol; 1994 Dec; 152(6 Pt 2):2308-11. PubMed ID: 7966729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population.
    Montoya L; Saiz I; Rey G; Vela F; Clerici-Larradet N
    Eur J Immunogenet; 1998 Oct; 25(5):329-37. PubMed ID: 9805655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaginal immunization of monkeys against urinary tract infection with a multi-strain vaccine.
    Uehling DT; Hopkins WJ; James LJ; Balish E
    J Urol; 1994 Jan; 151(1):214-6. PubMed ID: 8254817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization against urinary tract infection with a multi-valent vaginal vaccine.
    Uehling DT; James LJ; Hopkins WJ; Balish E
    J Urol; 1991 Jul; 146(1):223-6. PubMed ID: 2056594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA and hepatitis B infection.
    Almarri A; Batchelor JR
    Lancet; 1994 Oct; 344(8931):1194-5. PubMed ID: 7934542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood group antigen expression on vaginal cells and mucus in women with and without a history of urinary tract infections.
    Navas EL; Venegas MF; Duncan JL; Anderson BE; Kanerva C; Chmiel JS; Schaeffer AJ
    J Urol; 1994 Aug; 152(2 Pt 1):345-9. PubMed ID: 8015068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study of major histocompatibility complex and red blood cell antigen phenotypes as risk factors for recurrent urinary tract infections in women.
    Hopkins WJ; Heisey DM; Lorentzen DF; Uehling DT
    J Infect Dis; 1998 May; 177(5):1296-301. PubMed ID: 9593015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, immunogenicity, and preliminary clinical efficacy of a vaccine against extraintestinal pathogenic Escherichia coli in women with a history of recurrent urinary tract infection: a randomised, single-blind, placebo-controlled phase 1b trial.
    Huttner A; Hatz C; van den Dobbelsteen G; Abbanat D; Hornacek A; Frölich R; Dreyer AM; Martin P; Davies T; Fae K; van den Nieuwenhof I; Thoelen S; de Vallière S; Kuhn A; Bernasconi E; Viereck V; Kavvadias T; Kling K; Ryu G; Hülder T; Gröger S; Scheiner D; Alaimo C; Harbarth S; Poolman J; Fonck VG
    Lancet Infect Dis; 2017 May; 17(5):528-537. PubMed ID: 28238601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased immunologic responsiveness following intensified vaginal immunization against urinary tract infection.
    Uehling DT; Hopkins WJ; Balish E
    J Urol; 1990 Jan; 143(1):143-5. PubMed ID: 2403596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA antigens in multiple sclerosis of northern Spanish population.
    López-Larrea C; Uría DF; Coto E
    J Neurol Neurosurg Psychiatry; 1990 May; 53(5):434-5. PubMed ID: 2351974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Vaginal Microbiota and Urinary Tract Infection.
    Stapleton AE
    Microbiol Spectr; 2016 Dec; 4(6):. PubMed ID: 28087949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal immunization with fusion protein MrpH·FimH and MPL adjuvant confers protection against urinary tract infections caused by uropathogenic Escherichia coli and Proteus mirabilis.
    Habibi M; Asadi Karam MR; Shokrgozar MA; Oloomi M; Jafari A; Bouzari S
    Mol Immunol; 2015 Apr; 64(2):285-94. PubMed ID: 25562574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bacterial adherence and immune response in recurrent urinary tract infection.
    Suman E; Gopalkrishna Bhat K; Hegde BM
    Int J Gynaecol Obstet; 2001 Dec; 75(3):263-8. PubMed ID: 11728487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis.
    Naber KG; Cho YH; Matsumoto T; Schaeffer AJ
    Int J Antimicrob Agents; 2009 Feb; 33(2):111-9. PubMed ID: 18963856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human leukocyte antigens in women with recurrent urinary tract infections.
    Schaeffer AJ; Radvany RM; Chmiel JS
    J Infect Dis; 1983 Sep; 148(3):604. PubMed ID: 6604762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.